Zogenix files for $86M initial public offering

Zogenix is testing the chilly public waters with an IPO filing designed to raise up to $86.25 million. Banc of America Securities, Leerink Swann, Thomas Weisel Partners, and Susquehanna Financial Group are listed as underwriters for the San Diego-based developer, which is backed by Domain Associates, Clarus Lifesciences, Scale Venture Partners, Thomas McNerney & Partners, Abingworth Bioventures.

Last week Zogenix announced that the FDA had accepted its NDA for sumatriptan DosePro for the acute treatment of migraine attacks. Zogenix has raised about $80 million in venture funds to date and is developing therapies for neurology and pain.

- check out this release
- read the report from Socaltech

Related Articles:
Zogenix sells stock. Report
Zogenix gains $60M in new VC funds. Report

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.